Literature DB >> 6870377

Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients.

C M Balch, A B Tilden, P A Dougherty, G A Cloud.   

Abstract

The HNK-1 (Leu-7) monoclonal antibody was used to enumerate and characterize the level of blood granular lymphocytes in 247 cancer patients. The results were compared to 146 control individuals. A fluorescence-activated cell sorter was used to purify blood HNK-1+ cells from cancer patients. The monoclonal antibody identified a homogeneous population of granular lymphocytes with greater than 95% purity. Conversely, virtually 100% of HNK-1- cells from cancer patients were agranular lymphocytes. These results were the same as previously observed in normal individuals, where the HNK-1+ cell fraction contained all the lymphocytes with spontaneous cytotoxicity in natural killer (NK) and killer (K) cell assays. The level of HNK-1+ cells in cancer patients correlated significantly with the patient's age and sex, with older individuals having higher levels and male patients containing a higher proportion than female patients. The levels in the cancer patients were significantly lower than normal controls (p = 0.04). When the results were subdivided by the histologic type of cancer, additional differences were noted. Compared to age and sex-matched controls, significantly depressed levels of HNK-1+ granular lymphocytes were observed in 49 patients with colon cancer (9.7% vs. 15.8%, p = 0.0001), 18 patients with lung carcinoma (11.7% vs. 27.0%, p = 0.0001), 24 patients with breast carcinoma (12.0% vs. 15.5%, p = 0.04) and 64 patients with head and neck carcinoma (15.9% vs. 19.1%, p = 0.05). However, there were no significant differences overall in the average HNK-1+ cell level of 66 patients with melanoma (13.0% vs. 13.5%, p = 0.75) and nine patients with sarcomas (15.8% vs. 14.3%, p = 0.71). Thus, this important subpopulation of granular lymphocytes with NK and K cell function was significantly depressed in most cancer patients. Accounting for the patient's age and sex and the histologic type of cancer was critical to interpreting the results.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870377      PMCID: PMC1353079          DOI: 10.1097/00000658-198308000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells.

Authors:  W H West; G B Cannon; H D Kay; G D Bonnard; R B Herberman
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

Review 2.  The immune response to virally determined tumor associated antigens.

Authors:  E W Lamon
Journal:  Biochim Biophys Acta       Date:  1974-09-09

3.  Immunofluorescent studies of the development of pre-B cells, B lymphocytes and immunoglobulin isotype diversity in humans.

Authors:  W E Gathings; A R Lawton; M D Cooper
Journal:  Eur J Immunol       Date:  1977-11       Impact factor: 5.532

4.  Detection of human T cells using anti-monkey thymocyte antisera. Tissue distribution and evidence for antigenic heterogeneity.

Authors:  C M Balch; P A Dougherty; M K Dagg; A G Diethelm; A R Lawton
Journal:  Clin Immunol Immunopathol       Date:  1977-11

5.  Cellular immune reaction to human malignant melanoma and breast carcinoma cells.

Authors:  S Canevari; G Fossati; G Della Porta
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

6.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.

Authors:  R B Herberman; M E Nunn; H T Holden; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

7.  Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line.

Authors:  R Kiessling; G Petranyi; G Klein; H Wigzel
Journal:  Int J Cancer       Date:  1975-06-15       Impact factor: 7.396

8.  Spontaneous human lymphocyte-mediated cytotoxicity againts tumour target cells. I. The effect of malignant disease.

Authors:  H F Pross; M G Baines
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

9.  Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression.

Authors:  M Takasugi; A Ramseyer; J Takasugi
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

10.  Discordance among cell-mediated cytolytic mechanisms in cancer patients: importance of the assay system.

Authors:  W J Catalona; T L Ratliff; R E McCool
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

View more
  15 in total

1.  Lymphocyte subsets in subjects exposed to asbestos: changes in circulating natural killer cells.

Authors:  N al Jarad; M Macey; S Uthayakumar; A C Newland; R M Rudd
Journal:  Br J Ind Med       Date:  1992-11

2.  Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.

Authors:  K Eckert; E Grünberg; P Immenschuh; F Garbin; E D Kreuser; H R Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  [Immune status of patients with bronchial cancer].

Authors:  P Aulenbacher; H G Manke; P Drings
Journal:  Klin Wochenschr       Date:  1987-05-15

4.  Immunological analysis and characterization of lymphocyte subsets in specimens of human hepatocellular carcinomas and metastatic liver cancers.

Authors:  K Yuh; M Shimizu; S Aoyama; I Ichihara; H Watanabe; M Okumura; M Kikuchi
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer cell immunity for clinical use in cancer.

Authors:  Hyung Gun Maeng; Su Jin Lee; Yun A Lee; Hye Jeong Lee; Young Joo Kim; Jong Kyun Lee; Jae Cheol Kim; Joungbum Choi
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

6.  Loss of natural killer activity as an indicator of relapse in acute leukaemia.

Authors:  J A Tratkiewicz; J Szer
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

7.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.

Authors:  A Balsari; R Marolda; C Gambacorti-Passerini; G Sciorelli; G Tona; E Cosulich; D Taramelli; G Fossati; G Parmiani; N Cascinelli
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.

Authors:  J R Monson; C W Ramsden; G R Giles; T G Brennan; P J Guillou
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

10.  Depressed level of natural killer cells in cancer family syndrome.

Authors:  G Guanti; S Massari; G Cristofaro; M L Caruso; R Porsia; A Stella; F Susca; A Tauro; I Giorgio
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.